Duloxetine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoarthritis of the Knee
Conditions
Osteoarthritis of the Knee
Trial Timeline
Jan 1, 2015 → Mar 1, 2016
NCT ID
NCT02335346About Duloxetine
Duloxetine is a phase 3 stage product being developed by Shionogi for Osteoarthritis of the Knee. The current trial status is completed. This product is registered under clinical trial identifier NCT02335346. Target conditions include Osteoarthritis of the Knee.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02335346 | Phase 3 | Completed |
| NCT01914666 | Phase 3 | Completed |
| NCT01621191 | Phase 3 | Completed |
Competing Products
20 competing products in Osteoarthritis of the Knee